REGENERON PHARMACEUTICALS INC. - COMMON STOCK

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

19 Aug 2026 09:45:48 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

09 Jan 2026 10:12:07 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

08 Jan 2026 10:32:52 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

07 Jan 2026 09:54:13 By NetDania Notify

Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026

02 Jan 2026 16:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

24 Dec 2025 09:47:09 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

23 Dec 2025 10:01:35 By NetDania Notify

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

23 Dec 2025 01:00:00 By Nasdaq GlobeNewswire

Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

22 Dec 2025 16:05:00 By Nasdaq GlobeNewswire

Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

07 Dec 2025 16:30:00 By Nasdaq GlobeNewswire

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

01 Dec 2025 07:00:00 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

25 Nov 2025 01:00:00 By Nasdaq GlobeNewswire

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

19 Nov 2025 16:10:00 By Nasdaq GlobeNewswire

Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation

19 Nov 2025 07:00:00 By Nasdaq GlobeNewswire

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

13 Nov 2025 07:00:00 By Nasdaq GlobeNewswire

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

08 Nov 2025 10:46:31 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review

07 Nov 2025 08:00:00 By Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

03 Nov 2025 16:05:00 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

31 Oct 2025 07:00:00 By Nasdaq GlobeNewswire

Regeneron Reports Third Quarter 2025 Financial and Operating Results

28 Oct 2025 06:30:00 By Nasdaq GlobeNewswire